Trials in Brazil show the Chinese COVID-19 vaccine Sinovac to be 50.38% effective, nearly 30 percentage points below the initial results released last week. The Instituto Butantan, the São Paulo-based research institute responsible for developing the vaccine and conducting trials in the country, announced last week the vaccine had a 78% overall efficacy, with total protection against severe cases.
A coronavirus vaccine developed by China's Sinovac Biotech was 78% effective in a late-stage Brazilian trial with no severe COVID-19 cases, researchers said on Thursday, although a lack of data details stirred calls for more transparency.
Brazilian researchers said on Wednesday the COVID-19 vaccine developed by China's Sinovac Biotech is more than 50% effective based on trial data, but again withheld full results at the company's request, raising questions about transparency.
Chinese vaccine maker Sinovac Biotech Ltd's Covid-19 vaccine has shown to be effective in late-stage trials in Brazil, the Wall Street Journal reported on Monday, citing people involved in the vaccine's development.
Brazil’s health regulator Anvisa said China’s health authorities are not transparent in their authorization of COVID-19 vaccines for emergency use, a statement that may further inflame political tension in the country.
Brazil's Sao Paulo state delayed on Monday the release of efficacy data for the COVID-19 vaccine developed by China's Sinovac, tightening the timeframe for the regulator approval before a planned roll out on Jan. 25.
Brazil's government will of course buy a Chinese COVID-19 vaccine that is being tested in the country, Vice President Hamilton Mourão said on Friday, in the latest example of him contradicting President Jair Bolsonaro.